Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05350423 · ClinicalTrials.gov registry record · NA
Trial Assessing Renal Damage During Ureteroscopy
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT05350423 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 108 participants.
The verdict
NCT05350423, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is an ongoing randomized controlled trial of patients undergoing URSLL with unilateral non-obstructing renal stones. Patients are randomized to undergo URSLL with either the TFL or Ho:YAG laser. Each patient's urine is collected immediately pre-op (V1), 1 hour post-op (V2), and 10 days post-op (POD#10, V3). Samples are analyzed by enzyme-linked immunosorbent assay (ELISA) for the following biomarkers: Kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), and β2-microglobulin (β2M), then normalized to urine creatinine.
Interventions
- DEVICE Thulium Fibre Laser
- DEVICE Holmium:Yttrium-Aluminum-Garnet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2022-11-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05350423
The ClinicalTrials.gov registry entry for NCT05350423 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thulium Fibre Laser is the first listed.
NCT05350423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05350423 about?
NCT05350423 is a clinical study titled "Trial Assessing Renal Damage During Ureteroscopy". This is an ongoing randomized controlled trial of patients undergoing URSLL with unilateral non-obstructing renal stones. Patients are randomized to undergo URSLL with either the TFL or Ho:YAG laser. Each patient's urine is collected immediately pre-op (V1), 1 hour post-op (V2), and 10 days post-op ...
What is the current status of trial NCT05350423?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2021-10-22. Estimated completion is 2022-11-28.
What interventions are being tested in trial NCT05350423?
The interventions under investigation include: Thulium Fibre Laser (DEVICE), Holmium:Yttrium-Aluminum-Garnet (DEVICE).
Who is sponsoring clinical trial NCT05350423?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.